Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
SANOFI
Mr. Deepak Arora · Mumbai, India · 1,097 employees
₹3,419.90
▲+1.69%Sanofi is a global pharmaceutical giant trading significantly below its 52-week high, offering a compelling dividend yield amid revenue contraction but with strong analyst support.
Exchange
NSI
Currency
INR
Day range
₹3,378.10 – ₹3,450.00
52-week range
₹3,054.00 – ₹5,924.50
Sector
Healthcare
Industry
Drug Manufacturers - General
AI investment rating
AI analysis75% confidence
The stock appears undervalued relative to its 52-week range, trading near the lower third, with a P/E of 25.42 suggesting reasonable valuation for a quality pharma stock with a 7.14% dividend yield.
42.3% below the 1-year high · trend up
Hedge-fund memo
Today
The stock is up 1.69% today, trading in the lower portion of its day range with moderate volume.
This week
—
This month
—
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Bullish
23 headlines · 21 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 2 recent quarters (EPS actual vs. consensus).
44.55 vs 42.8
4.09% surprise
26.79 vs 41.8
-35.91% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| SANOFI | 78.76B | 25.42 | — | 28.33% | -11.90% |
| ABBOTINDIA | 589.56B | 37.95 | 34.46% | 27.02% | 6.50% |
| PFIZER | 217.54B | 29.60 | 17.16% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Revenue contraction continuing beyond current quarter
Mitigation: Monitor pipeline developments and new product launches
Increased regulatory hurdles in key markets
Mitigation: Diversified geographic presence helps mitigate single-market risk
Business intelligence
Competitive moat
Global scale, diversified therapeutic portfolio, and established R&D capabilities provide competitive advantages in the pharmaceutical industry.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
FDA decisions on pipeline products
Earnings report showing revenue stabilization
Thesis builder
Bull case
Strong product portfolio and pipeline could drive recovery in revenue growth, with current valuation offering attractive entry point.
Base case
Maintains stable profitability with 17.46% profit margin and high institutional ownership, providing downside protection despite revenue decline.
Bear case
Persistent revenue contraction and potential patent losses could pressure margins and valuation multiple.
Time horizon
12-24 months
Est. CAGR
5-8%
Entry (qual.)
Current levels near 52-week low offer attractive entry for long-term investors
Exit (qual.)
Consider taking profits above 4500-5000 levels, near previous trading ranges
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how SANOFI fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain SANOFI for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Buy for income investors with moderate risk tolerance, considering the attractive dividend and analyst support despite near-term revenue challenges.
chennaipatrika.com·6h ago·strong Q2 results India
Exchange4Media·8h ago·executive departure
business-standard.com·14h ago·profit up 13% Q2
Indian Pharma Post·14h ago·revenue up 7% PBT up
koreabiomed.com·15h ago·partnership Korea healthcare
GuruFocus·20h ago·stock up 3.5% undervalued
biz.chosun.com·20h ago·unrelated stocks watchlist
Moneycontrol.com·21h ago·Q1 profit up 13%
Fortune India·1d ago·profit up 13% domestic
Whalesbook·1d ago·Q2 profit up margins up
CNBC TV18·1d ago·Q2 profit up YoY
scanx.trade·1d ago·Q1 profit up YoY
Sahi·1d ago·Hindi strong Q2 profit
Whalesbook·1d ago·Q2 profit 688M rupees
TradingView·1d ago·executive oncology talk
BioXconomy·1d ago·drug development halted
businesspost.ie·1d ago·earnings preview neutral
TradingView·1d ago·AI rare disease tool
The Economic Times·1d ago·portfolio disclosure
Stock Titan·1d ago·therapeutic research
sanofi.com·1d ago·technical breakout signal
marketscreener.com·1d ago·drug development halted
아시아경제·1d ago·investee company update
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 35.25% |
| 6.30% |
| ALKEM | 678.23B | 29.43 | 17.56% | 11.42% | 14.60% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹3,378.10
Resistance (day/52w high)
₹3,450.00
Volume
1,48,364
Trend
up
RSI (14)
60
MACD
bearish
MA cross
death
50-day MA
₹3,306.03
200-day MA
₹3,796.62
vs 200-DMA
-9.9%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.